NYXOAH SA (NYXH.BR) Stock Fundamental Analysis
Europe - EBR:NYXH - BE0974358906 - Common Stock
4.06 EUR
+0.06 (+1.5%)
We assign a fundamental rating of 2 out of 10 to NYXH. NYXH was compared to 60 industry peers in the Health Care Equipment & Supplies industry. NYXH has a bad profitability rating. Also its financial health evaluation is rather negative. NYXH is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
NYXH had negative earnings in the past year.
In the past year NYXH has reported a negative cash flow from operations.
NYXH had negative earnings in each of the past 5 years.
NYXH had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -66.28%, NYXH is doing worse than 90.00% of the companies in the same industry.
Looking at the Return On Equity, with a value of -105.18%, NYXH is doing worse than 81.67% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -66.28% | ||
| ROE | -105.18% | ||
| ROIC | N/A |
ROA(3y)-31.19%
ROA(5y)-24.1%
ROE(3y)-40.78%
ROE(5y)-30.7%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a decent Gross Margin value of 65.27%, NYXH is doing good in the industry, outperforming 68.33% of the companies in the same industry.
In the last couple of years the Gross Margin of NYXH has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for NYXH so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 65.27% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.63%
GM growth 5YN/A
2. Health
2.1 Basic Checks
NYXH does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, NYXH has more shares outstanding
The number of shares outstanding for NYXH has been increased compared to 5 years ago.
NYXH has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -2.60, we must say that NYXH is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -2.60, NYXH is not doing good in the industry: 83.33% of the companies in the same industry are doing better.
A Debt/Equity ratio of 0.29 indicates that NYXH is not too dependend on debt financing.
NYXH has a Debt to Equity ratio (0.29) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.29 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.6 |
ROIC/WACCN/A
WACC7.29%
2.3 Liquidity
NYXH has a Current Ratio of 2.63. This indicates that NYXH is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of NYXH (2.63) is better than 73.33% of its industry peers.
NYXH has a Quick Ratio of 2.38. This indicates that NYXH is financially healthy and has no problem in meeting its short term obligations.
NYXH has a Quick ratio of 2.38. This is in the better half of the industry: NYXH outperforms 80.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.63 | ||
| Quick Ratio | 2.38 |
3. Growth
3.1 Past
NYXH shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -30.80%.
The Revenue has been growing slightly by 3.98% in the past year.
NYXH shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 74.42% yearly.
EPS 1Y (TTM)-30.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-28.32%
Revenue 1Y (TTM)3.98%
Revenue growth 3Y74.42%
Revenue growth 5YN/A
Sales Q2Q%56.94%
3.2 Future
Based on estimates for the next years, NYXH will show a small growth in Earnings Per Share. The EPS will grow by 3.45% on average per year.
NYXH is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 117.81% yearly.
EPS Next Y-24.84%
EPS Next 2Y-8.36%
EPS Next 3Y3.45%
EPS Next 5YN/A
Revenue Next Year57.01%
Revenue Next 2Y156.82%
Revenue Next 3Y141.05%
Revenue Next 5Y117.81%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
NYXH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NYXH. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-8.36%
EPS Next 3Y3.45%
5. Dividend
5.1 Amount
NYXH does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
EBR:NYXH (11/19/2025, 3:30:04 PM)
4.06
+0.06 (+1.5%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners22.74%
Inst Owner ChangeN/A
Ins Owners22.07%
Ins Owner ChangeN/A
Market Cap151.97M
Revenue(TTM)4.52M
Net Income(TTM)-77.20M
Analysts81.43
Price Target12.19 (200.25%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-8.5%
Min EPS beat(2)-22.16%
Max EPS beat(2)5.16%
EPS beat(4)2
Avg EPS beat(4)-4.61%
Min EPS beat(4)-22.16%
Max EPS beat(4)5.16%
EPS beat(8)6
Avg EPS beat(8)2.91%
EPS beat(12)7
Avg EPS beat(12)-7.28%
EPS beat(16)9
Avg EPS beat(16)-4.34%
Revenue beat(2)0
Avg Revenue beat(2)-19.91%
Min Revenue beat(2)-38.43%
Max Revenue beat(2)-1.4%
Revenue beat(4)0
Avg Revenue beat(4)-21.65%
Min Revenue beat(4)-38.43%
Max Revenue beat(4)-1.4%
Revenue beat(8)1
Avg Revenue beat(8)-22.06%
Revenue beat(12)1
Avg Revenue beat(12)-32.46%
Revenue beat(16)1
Avg Revenue beat(16)-37%
PT rev (1m)-5.91%
PT rev (3m)-4.78%
EPS NQ rev (1m)-0.57%
EPS NQ rev (3m)-7.05%
EPS NY rev (1m)-5.7%
EPS NY rev (3m)-20.24%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-18.18%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-39.97%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 30.81 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 2.07 | ||
| P/tB | 6.91 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.25
EYN/A
EPS(NY)-2.12
Fwd EYN/A
FCF(TTM)-1.67
FCFYN/A
OCF(TTM)-1.63
OCFYN/A
SpS0.13
BVpS1.96
TBVpS0.59
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -66.28% | ||
| ROE | -105.18% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 65.27% | ||
| FCFM | N/A |
ROA(3y)-31.19%
ROA(5y)-24.1%
ROE(3y)-40.78%
ROE(5y)-30.7%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.63%
GM growth 5YN/A
F-Score3
Asset Turnover0.04
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.29 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 49.33% | ||
| Cap/Sales | 29.96% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.63 | ||
| Quick Ratio | 2.38 | ||
| Altman-Z | -2.6 |
F-Score3
WACC7.29%
ROIC/WACCN/A
Cap/Depr(3y)64.88%
Cap/Depr(5y)74.74%
Cap/Sales(3y)37.33%
Cap/Sales(5y)219.78%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-30.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-28.32%
EPS Next Y-24.84%
EPS Next 2Y-8.36%
EPS Next 3Y3.45%
EPS Next 5YN/A
Revenue 1Y (TTM)3.98%
Revenue growth 3Y74.42%
Revenue growth 5YN/A
Sales Q2Q%56.94%
Revenue Next Year57.01%
Revenue Next 2Y156.82%
Revenue Next 3Y141.05%
Revenue Next 5Y117.81%
EBIT growth 1Y-55.84%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-37.6%
EBIT Next 3Y-16.06%
EBIT Next 5Y11.04%
FCF growth 1Y-45.81%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-46.67%
OCF growth 3YN/A
OCF growth 5YN/A
NYXOAH SA / NYXH.BR FAQ
What is the fundamental rating for NYXH stock?
ChartMill assigns a fundamental rating of 2 / 10 to NYXH.BR.
What is the valuation status for NYXH stock?
ChartMill assigns a valuation rating of 0 / 10 to NYXOAH SA (NYXH.BR). This can be considered as Overvalued.
Can you provide the profitability details for NYXOAH SA?
NYXOAH SA (NYXH.BR) has a profitability rating of 1 / 10.